🇺🇸 sodium selenite pentahydrate in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. Device Related Infection — 2 reports (18.18%)
2. Anaemia — 1 report (9.09%)
3. Bronchitis — 1 report (9.09%)
4. Enteritis — 1 report (9.09%)
5. Headache — 1 report (9.09%)
6. Iron Deficiency Anaemia — 1 report (9.09%)
7. Medical Device Site Inflammation — 1 report (9.09%)
8. Nasopharyngitis — 1 report (9.09%)
9. Nausea — 1 report (9.09%)
10. Rash — 1 report (9.09%)

Source database →

Frequently asked questions

Is sodium selenite pentahydrate approved in United States?

sodium selenite pentahydrate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for sodium selenite pentahydrate in United States?

Seoul National University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.